Back to search

Article

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent manner

2023-02-16

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is associated with mutations in Kras, a known oncogenic driver of PDAC; and the KRAS G12D mutation is present in nearly half of PDAC patients. Recently, a non-covalent small molecule inhibitor (MRTX1133) was identified with specificity to the Kras G12D mutant protein. Here we explore the impact of Kras G12D inhibition by MRTX1133 on advanced PDAC and its influence on the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
53b2f793-8750-503f-9174-a93f75609cb9
DOI
10.1101/2023.02.15.528757
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerDOI 10.1101/2023.02.15.528757
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity
Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity
Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.Semantic proximity
CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC.Semantic proximity
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaSemantic proximity
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.Semantic proximity
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Semantic proximity
Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity
Select a neighboring publication to make it the new centre.